Discover investment opportunities in Cancer Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Cancer Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Cancer Stocks using our Smart AI Filter.
10 stocks found for "Cancer Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.22 | ±27.3% | 15.0 | 2.83% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
0.33 | ±27.9% | 8.6 | 4.00% | |||
0.59 | ±31.6% | 34.5 | 0.77% | |||
0.62 | ±41.3% | -11.5 | 0.00% | |||
0.63 | ±35.0% | 27.1 | 0.00% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
0.35 | ±28.9% | 6.7 | 5.29% | |||
0.45 | ±25.0% | 14.4 | 3.19% | |||
0.32 | ±24.8% | 8.7 | 6.75% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: Which cancer stock companies have a strong historical performance in terms of growth?
A: Companies like Eli Lilly (LLY) and Johnson & Johnson (JNJ) have historically shown strong growth in oncology through successful drug launches and acquisitions. Investors often view their commitment to research and development as a factor driving sustained performance.
Q: Are any of these cancer stocks known for reliable dividend payments?
A: Pfizer (PFE) and Merck (MRK) are noted for their robust dividend history, appealing to investors seeking income stability. However, dividend attractiveness should be assessed alongside payout ratios and company fundamentals.
Q: What are the sector-specific risks associated with investing in cancer stocks like Amgen (AMGN) or AstraZeneca (AZN)?
A: Cancer stocks face several risks, including drug development failure, regulatory challenges, and competitive pressures from generic drug manufacturers. These factors can impact stock volatility and long-term growth potential.
Q: How have stocks like Novartis (NVS) responded in past economic downturns?
A: Historically, Novartis and similar pharmaceutical firms often display resilience during economic downturns, as demand for healthcare products remains relatively stable. Nonetheless, past performance is not a guarantee of future results.
Q: What makes Roche Holding (RHHBY) a competitive player in the oncology sector?
A: Roche's strong pipeline and innovative therapies in targeted cancer treatments provide a competitive edge. Its collaborations and acquisitions further bolster its position in the oncology market.
Q: Which companies among these are leading in innovation within the oncology field?
A: Gilead Sciences (GILD) and Bristol Myers Squibb (BMY) are recognized for their innovative approaches, particularly in developing novel therapies and leveraging biotechnology initiatives in cancer treatment.
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read morePresident Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.
Read more